What smart money is saying about Basilea
BSLN.SW
No fund has written a full thesis on Basilea in our archive, but 1 fund letter reports a position in it, most recently Acatis in October 2026.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in Basilea on record in the archive was reported in Q4 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2026 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- HoldsAcatisOctober 2026
“Veeva Systems increased by more than 50% since the end of June, and Oxford Nanopore Technologies doubled since the low in July. Genmab, Sysmex and Basilea generated double-digit gains.”
Basilea
Read the letters behind these Basilea positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger